Avicanna Inc. (AVCNF)

Market Cap	19.85M
Revenue (ttm)	18.30M
Net Income (ttm)	-1.35M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	51,045
Open	0.1650
Previous Close	0.1670
Day's Range	0.1650 - 0.1650
52-Week Range	0.1150 - 0.2650
Beta	0.43
RSI	48.06
Earnings Date	Mar 31, 2026

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 87
• Stock Exchange: OTCMKTS
• Ticker Symbol: AVCNF

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.

Financial numbers in CAD